[HTML][HTML] Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics
MN Bhaoighill, EA Dunlop - Cancer Drug Resistance, 2019 - ncbi.nlm.nih.gov
Delineating the contributions of specific cell signalling cascades to the development and
maintenance of tumours has greatly informed our understanding of tumorigenesis and has …
maintenance of tumours has greatly informed our understanding of tumorigenesis and has …
[HTML][HTML] High-mobility group box 1 (HMGB1) promotes angiogenesis and tumor migration by regulating hypoxia-inducible factor 1 (HIF-1α) expression via the …
H He, X Wang, J Chen, L Sun, H Sun… - Medical science monitor …, 2019 - ncbi.nlm.nih.gov
Background High-mobility group box 1 (HMGB1) is an essential contributor towards initiation
and progression of many kinds of cancers. Nevertheless, our understanding of the molecular …
and progression of many kinds of cancers. Nevertheless, our understanding of the molecular …
[HTML][HTML] Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
PH Lin, LM Tseng, YH Lee, ST Chen, DC Yeh… - Journal of the Formosan …, 2022 - Elsevier
Background The prognosis of triple-negative breast cancer (TNBC) is worse and a major
proportion of TNBC expresses epidermal growth factor receptor (EGFR). Afatinib can inhibit …
proportion of TNBC expresses epidermal growth factor receptor (EGFR). Afatinib can inhibit …
[HTML][HTML] Everolimus inhibits the proliferation and migration of epidermal growth factor receptor‑resistant lung cancer cells A549 via regulating the microRNA‑4328 …
X Xiang, L Zhuang, H Chen, X Yang… - Oncology …, 2019 - spandidos-publications.com
Lung cancer is the most common cancer type worldwide, and investigating novel
therapeutics methods for the treatment of chemoresistant lung cancer are of notable clinical …
therapeutics methods for the treatment of chemoresistant lung cancer are of notable clinical …
Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer
A Mazumdar, WM Tahaney, JL Hill, Y Zhang… - Cancer Prevention …, 2022 - AACR
Prevention of estrogen receptor (ER)-positive breast cancer is now possible using anti-
estrogen drugs; however, this treatment is ineffective against ER-negative breast cancers. In …
estrogen drugs; however, this treatment is ineffective against ER-negative breast cancers. In …
The role of PDK1 in PI3K-driven intestinal carcinogenesis
M Lei - 2021 - mediatum.ub.tum.de
C degree Celsius 3D three-dimensional AB alcian blue AF aelle frequency AMP adenosine
monophosphate ATP adenosine triphosphate AMN appendiceal mucinous neoplasm Apc …
monophosphate ATP adenosine triphosphate AMN appendiceal mucinous neoplasm Apc …